Andrew Preece

814 total citations
29 papers, 675 citations indexed

About

Andrew Preece is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Analytical Chemistry. According to data from OpenAlex, Andrew Preece has authored 29 papers receiving a total of 675 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pulmonary and Respiratory Medicine, 14 papers in Physiology and 6 papers in Analytical Chemistry. Recurrent topics in Andrew Preece's work include Asthma and respiratory diseases (14 papers), Inhalation and Respiratory Drug Delivery (12 papers) and Chronic Obstructive Pulmonary Disease (COPD) Research (10 papers). Andrew Preece is often cited by papers focused on Asthma and respiratory diseases (14 papers), Inhalation and Respiratory Drug Delivery (12 papers) and Chronic Obstructive Pulmonary Disease (COPD) Research (10 papers). Andrew Preece collaborates with scholars based in United Kingdom, United States and Netherlands. Andrew Preece's co-authors include Kenth Gustafsson, Karen Strahan, Rashmi Mehta, Mary Collins, Robin A. Weiss, Yasuhiro Takeuchi, François–Loïc Cosset, Dennis Kelleher, Glenn Crater and Anthony Cahn and has published in prestigious journals such as Nature, Blood and PLoS ONE.

In The Last Decade

Andrew Preece

29 papers receiving 659 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Andrew Preece United Kingdom	13	305	293	202	158	106	29	675
John D. Broussard United States	14	194 0.6×	40 0.1×	81 0.4×	110 0.7×	45 0.4×	18	576
T. D. Brogan United Kingdom	11	175 0.6×	65 0.2×	25 0.1×	77 0.5×	84 0.8×	24	444
Houria Abdelghaffar France	11	96 0.3×	49 0.2×	47 0.2×	27 0.2×	68 0.6×	24	433
Susanna E. Schlegel‐Haueter Switzerland	9	99 0.3×	37 0.1×	123 0.6×	56 0.4×	111 1.0×	16	669
Pamela Rogers United States	4	53 0.2×	99 0.3×	23 0.1×	50 0.3×	43 0.4×	7	334
K Kawakami Japan	12	352 1.2×	204 0.7×	20 0.1×	56 0.4×	84 0.8×	26	709
Vipul V. Jain United States	14	228 0.7×	477 1.6×	18 0.1×	23 0.1×	125 1.2×	26	851
Mukesh Kumar Singh India	10	31 0.1×	30 0.1×	135 0.7×	101 0.6×	180 1.7×	43	464
M Hvatum Norway	13	65 0.2×	69 0.2×	36 0.2×	63 0.4×	53 0.5×	20	482
Carrie‐Anne Malinczak United States	14	122 0.4×	87 0.3×	22 0.1×	65 0.4×	98 0.9×	25	468

Countries citing papers authored by Andrew Preece

Since Specialization

Citations

This map shows the geographic impact of Andrew Preece's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Preece with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Preece more than expected).

Fields of papers citing papers by Andrew Preece

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew Preece. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Preece. The network helps show where Andrew Preece may publish in the future.

Co-authorship network of co-authors of Andrew Preece

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew Preece. A scholar is included among the top collaborators of Andrew Preece based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew Preece. Andrew Preece is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Moore, Alison, Andrew Preece, Raj Kumar Sharma, et al.. (2020). A randomised controlled trial of the effect of a connected inhaler system on medication adherence in uncontrolled asthmatic patients. European Respiratory Journal. 57(6). 2003103–2003103. 45 indexed citations

Kerwin, Edward, et al.. (2019). ELLIPTA Dry Powder Versus Metered-Dose Inhalers in an Optimized Clinical Trial Setting. The Journal of Allergy and Clinical Immunology In Practice. 7(6). 1843–1849. 7 indexed citations

Palen, Job van der, C. Dawson, W. R. L. James, et al.. (2018). A randomized, open-label, single-visit crossover study simulating triple-drug delivery with Ellipta compared with dual inhaler combinations in patients with COPD. International Journal of COPD. Volume 13. 2515–2523. 28 indexed citations

Prime, David, Wilfried De Backer, Melanie Hamilton, et al.. (2015). Effect of Disease Severity in Asthma and Chronic Obstructive Pulmonary Disease on Inhaler-Specific Inhalation Profiles Through the ELLIPTA ^® Dry Powder Inhaler. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 28(6). 486–497. 49 indexed citations

Kelleher, Dennis, Lee Tombs, Andrew Preece, Noushin Brealey, & Rashmi Mehta. (2014). A randomized, placebo- and moxifloxacin-controlled thorough QT study of umeclidinium monotherapy and umeclidinium/vilanterol combination in healthy subjects. Pulmonary Pharmacology & Therapeutics. 29(1). 49–57. 17 indexed citations

Mehta, Rashmi, Kelly Hardes, Dennis Kelleher, et al.. (2014). Effects of Moderate Hepatic Impairment on the Pharmacokinetic Properties and Tolerability of Umeclidinium and Vilanterol in Inhalational Umeclidinium Monotherapy and Umeclidinium/Vilanterol Combination Therapy: An Open-Label, Nonrandomized Study. Clinical Therapeutics. 36(7). 1016–1027.e2. 10 indexed citations

Mehta, Rashmi, Kelly Hardes, Noushin Brealey, et al.. (2014). Effect of severe renal impairment on umeclidinium and umeclidinium/vilanterol pharmacokinetics and safety: a single-blind, nonrandomized study. International Journal of COPD. 10. 15–15. 10 indexed citations

Mehta, Rashmi, et al.. (2013). Safety, pharmacodynamics (PD) and pharmacokinetics (PK) of darotropium (DARO) and vilanterol (VI) in healthy subjects: Two phase 1 studies. 42. 691. 2 indexed citations

Mehta, Rashmi, et al.. (2013). Effect of verapamil on systemic exposure and safety of umeclidinium and vilanterol: a randomized and open-label study. International Journal of COPD. 8. 159–159. 28 indexed citations

10.

Mehta, Rashmi, Kelly Hardes, Dennis Kelleher, et al.. (2013). Effect of moderate hepatic impairment (MHI) on umeclidinium (UMEC) and vilanterol (VI) pharmacokinetics (PK). 42. 3641. 3 indexed citations

11.

Cahn, Anthony, Ruth Tal‐Singer, Isabelle Pouliquen, et al.. (2013). Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Inhaled Doses of Umeclidinium in Healthy Subjects: Two Randomized Studies. Clinical Drug Investigation. 33(7). 477–488. 21 indexed citations

12.

Kelleher, Dennis, Kelly Hardes, Noushin Brealey, et al.. (2013). Effect of severe renal impairment (SRI) on umeclidinium (UMEC) and vilanterol (VI) pharmacokinetics (PK). 42. 4148. 4 indexed citations

13.

Tal‐Singer, Ruth, Anthony Cahn, Rashmi Mehta, et al.. (2012). Initial assessment of single and repeat doses of inhaled umeclidinium in patients with chronic obstructive pulmonary disease: Two randomised studies. European Journal of Pharmacology. 701(1-3). 40–48. 27 indexed citations

14.

Kelleher, Dennis, Andrew Preece, Rashmi Mehta, et al.. (2011). Phase II study of once-daily GSK573719 inhalation powder, a new long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD). European Respiratory Journal. 38(Suppl 55). p834–p834. 4 indexed citations

15.

Mehta, Rashmi, Amy Newlands, Dennis Kelleher, et al.. (2011). Safety, pharmacokinetics (PK) and pharmacodynamics (PD) of single doses of GSK573719 inhalation powder, a new long-acting muscarinic antagonist (LAMA), in patients with COPD. European Respiratory Journal. 38(Suppl 55). p822–p822. 7 indexed citations

16.

Dürrbach, Antoine, Emma L. Baple, Andrew Preece, Bernard Charpentier, & Kenth Gustafsson. (2007). Virus recognition by specific natural antibodies and complement results in MHC I cross‐presentation. European Journal of Immunology. 37(5). 1254–1265. 23 indexed citations

17.

Preece, Andrew, et al.. (2002). Expression of ABO or related antigenic carbohydrates on viral envelopes leads to neutralization in the presence of serum containing specific natural antibodies and complement. Blood. 99(7). 2477–2482. 60 indexed citations

18.

Takeuchi, Yasuhiro, Karen Strahan, Andrew Preece, et al.. (1996). Sensitization of cells and retroviruses to human serum by (αl-3) galactosyltransferase. Nature. 379(6560). 85–88. 225 indexed citations

19.

Strahan, Karen, Andrew Preece, Yuanxin Xu, & Kenth Gustafsson. (1995). Antisense inhibition of pig α1,3galactosyl‐transferase leads to a reduction in expression of the major target for human natural antibodies on pig vascular endothelial cells. Xenotransplantation. 2(3). 143–147. 5 indexed citations

20.

Gustafsson, Kenth, Karen Strahan, & Andrew Preece. (1994). α1,3Galactosyltransferase: A Target for in vivo Genetic Manipulation in Xenotransplantation. Immunological Reviews. 141(1). 59–70. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact